Amifostine alone and in combination with erythropoietin for the treatment of favorable myelodysplastic syndrome

Ayalew Tefferi, Michelle A. Elliott, David P. Steensma, C. Christopher Hook, Angela Dispenzieria, Curtis A. Hanson, Georgene Schroeder, Louis Letendre

Research output: Contribution to journalArticle

19 Scopus citations

Abstract

Ten anemic patients with favorable myelodysplastic syndrome (MDS) were first treated with two 5-week courses of amifostine alone (each course consisted of 200 mg/m2 of the drug given intravenously three times a week for 3 weeks), followed by an additional two courses combined with subcutaneous erythropoietin (EPO) (150 U/kg, three times a week for 8 weeks). The study patients either had previously failed to respond to treatment with EPO or had pretreatment serum EPO levels of more than 100 mU/ml. None of the patients experienced a complete or partial response in anemia or other cytopenias. We conclude that amifostine alone or in combination with EPO has limited therapeutic activity in MDS.

Original languageEnglish (US)
Pages (from-to)183-185
Number of pages3
JournalLeukemia Research
Volume25
Issue number2
DOIs
StatePublished - Feb 20 2001

Keywords

  • Amifostine
  • Anemia
  • Cytopenia
  • Differentiating therapy
  • Erythropoietin
  • Myelodysplastic syndromes

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Amifostine alone and in combination with erythropoietin for the treatment of favorable myelodysplastic syndrome'. Together they form a unique fingerprint.

  • Cite this

    Tefferi, A., Elliott, M. A., Steensma, D. P., Hook, C. C., Dispenzieria, A., Hanson, C. A., Schroeder, G., & Letendre, L. (2001). Amifostine alone and in combination with erythropoietin for the treatment of favorable myelodysplastic syndrome. Leukemia Research, 25(2), 183-185. https://doi.org/10.1016/S0145-2126(00)00108-9